Sustainability Edge Leverage Alkion's carbon-neutral, resource-efficient bioproduction platform to position as a supplier of sustainable plant-derived APIs, complex extracts, and recombinant proteins for pharmaceutical and agri-food markets, appealing to buyers prioritizing ESG credentials.

Global Vaccine Access Target opportunities around large-scale production of QS immunoenhancers to support global vaccination programs, especially in the Global South, highlighting capacity to scale toward billions of doses at lower cost while preserving biodiversity.

Strategic Partnerships Propose collaborations with European partners and NGOs to co-develop in vitro bioproduction platforms, enabling risk-sharing, faster time-to-market, and access to grant funding or subsidized pilots that de-risk early engagements for potential buyers.

Cannabinoids & CNS Explore interest from pharmaceutical and biotech customers for standardized cannabinoid APIs and extracts for CNS indications, leveraging Alkion’s historical licensing and regulatory familiarity to accelerate regulatory-ready product pipelines.

Agri-Food Innovation Position the sweet protein biosynthesis program as a high-value sugar substitute and revenue boost for farmers, offering co-development pilots with food and beverage manufacturers seeking clean-label, functional sweeteners with scalable plant-based sourcing.